Tarsus Pharmaceuticals, Inc. (TARS) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-23
Business type: Asset play
How it makes money
Patients and insurers pay for XDEMVY to treat mite-related eyelid inflammation.
Sales come from XDEMVY, a drug used to kill mites that cause eyelid inflammation. In 2025, the company sold 400,000 bottles, generating $451.4 million in net sales.
The company drives these sales through television and streaming ads, which increased patient awareness from 2% to 25%.
What protects it: the moat
Management claims the company has a monopoly as the only FDA-approved treatment.
TARS asserts that XDEMVY is the definitive standard of care for this specific eye condition.
There is currently no other FDA-approved drug to treat Demodex blepharitis.
What could damage it
The company's entire revenue depends on its single approved product.
TARS currently has only one product, XDEMVY, approved for commercial sale.
If this one product is replaced by a competitor or loses its market exclusivity, the company's primary source of cash would be lost.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.